文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

关键性医疗器械临床研究中的公平、多样性与包容性:近五年范围综述

Equity, diversity, and inclusion in pivotal medical device clinical investigations: a scoping review of studies published in the past 5 years.
PubMed 文献 · J Clin Epidemiol · 2026-06-12

该范围综述按JBI与PRISMA-ScR标准检索MEDLINE、Embase和Cochrane CENTRAL近五年文献,纳入74项关键性医疗器械临床研究(91.9%为随机对照试验)。研究发现年龄和性别几乎均被报告,但纳入分析框架有限;种族/族裔报告率35.1%,其他PROGRESS-Plus变量仅9.5%,明确EDI框架仅2.7%,无研究应用CONSORT-Equity或进行人群基准比较。

要点

  • 关键性器械试验常规报告年龄和性别,但仅18.9%和14.8%分别做年龄、性别亚组分析。
  • 种族/族裔报告率35.1%且极少纳入结局分析,其他PROGRESS-Plus变量仅9.5%。
  • 无研究进行人群代表性基准比较,结构性参与障碍仅12.2%被提及。

核心结论

  • 关键性器械研究常规报告基本人口学特征,但很少在设计或分析中嵌入结构性公平考量。
  • 缺乏人群基准比较和有限的亚组评估限制了对研究外部有效性的评价。
  • 加强公平导向的报告与分析整合可能提升支持器械审批和临床使用证据的包容性与适用性。

研究设计与样本

  • 采用范围综述设计,遵循Joanna Briggs Institute指南和PRISMA-ScR报告标准。
  • 检索MEDLINE、Embase和Cochrane CENTRAL近五年发表的同行评议研究。
  • 纳入标准为旨在支持监管审批或提供安全有效性主要证据的关键性医疗器械人体临床研究。
  • 共纳入74项研究,其中68项(91.9%)为随机对照试验。
  • 数据提取框架参考PRO-EDI、PROGRESS-Plus、INCLUDE Ethnicity和CONSORT-Equity。

主要发现

  • 年龄和性别在几乎所有临床研究中均有报告,性别指原研究报告的参与者性别变量(男/女)。
  • 18.9%的研究进行了基于年龄的亚组分析,14.8%进行了基于性别的分析。
  • 35.1%的研究报告了种族/族裔,且极少纳入结局分析。
  • 仅9.5%的研究报告了其他PROGRESS-Plus变量。
  • 明确在试验设计、招募或分析中体现EDI框架的研究仅占2.7%,无研究应用CONSORT-Equity。

关键数值与推荐

  • 年龄和性别报告率接近全部,但年龄亚组分析仅18.9%、性别分析仅14.8%。
  • 种族/族裔报告率35.1%,其他PROGRESS-Plus变量报告率9.5%。
  • 明确EDI框架占比2.7%,CONSORT-Equity应用为0。
  • 结构性/程序性参与障碍(地理可及性、费用、时间负担、卫生系统限制)仅12.2%被提及。
  • 招募多基于临床机构,无研究进行人群基准比较或正式代表性分析。

临床怎么用

  • 解读关键性器械试验结果时需注意其人口学代表性有限,外推至多样人群应谨慎。
  • 开展器械临床试验时应预先设计公平相关亚组分析并报告PROGRESS-Plus变量。
  • 建议参照CONSORT-Equity等框架提升招募、分析与报告中的公平性整合。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Equity, diversity, and inclusion (EDI) considerations are increasingly emphasized in clinical research, yet their integration within pivotal medical device investigations remains unclear. This scoping review mapped how EDI principles are addressed in pivotal device clinical investigations across therapeutic areas. STUDY DESIGN AND SETTING: We conducted a scoping review in accordance with Joanna Briggs Institute guidance and Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews reporting standards. MEDLINE, Embase, and Cochrane CENTRAL were searched for peer-reviewed studies published within the past 5 years. Eligible studies were pivotal clinical investigations of medical devices-defined as studies intended to support regulatory approval or to provide primary evidence of safety and effectiveness-in human participants. Data were extracted using frameworks informed by PRO-EDI, PROGRESS-Plus, INCLUDE Ethnicity, and CONSORT-Equity, and synthesized across key domains, including reporting practices, recruitment and eligibility, population representation, and geographical variation. RESULTS: Seventy-four studies were included, predominantly randomized controlled trials (68/74, 91.9%). Age and sex were reported in almost all clinical investigations, with sex referring to the participant sex variable as reported by the original clinical investigation (male/female). Their integration into analytic framework was limited; 18.9% conducted age-based subgroup analyses, and 14.8% conducted sex-based analyses. Race/ethnicity was reported in 35.1% of studies and rarely incorporated into outcome analyses. Additional PROGRESS-Plus variables were reported in only 9.5% of studies. Explicit EDI framing within trial design, recruitment, or analysis was uncommon (2.7%), and no study applied CONSORT-Equity. Recruitment was largely clinic based, and none conducted population benchmarking or formal representativeness analyses. Structural and procedural barriers to participation, such as geographic access, cost, time burden, and health system constraints, were infrequently acknowledged (12.2%) and were rarely conceptualized as determinants of representation or incorporated into study design, recruitment strategies, or analytic frameworks. CONCLUSION: Pivotal device investigations routinely report basic demographics but rarely embed structured equity considerations in design or analysis. The absence of population benchmarking and limited subgroup evaluation constrain the assessment of external validity. Strengthening equity-oriented reporting and analytic integration in pivotal trials may enhance the inclusiveness and applicability of evidence supporting device approval and clinical use. PLAIN LANGUAGE SUMMARY: Medical devices are often tested in "pivotal" clinical trials before they receive regulatory approval and are used widely in health care. These trials must provide evidence that a device is safe and effective. It is important that the people taking part reflect the patients who will ultimately use the device. If certain groups are underrepresented, it becomes difficult to know whether the results apply equally to everyone. In this review, we examined how EDI are considered in recent pivotal clinical trials of medical devices. We looked at who was included, how participant characteristics were reported, and whether differences between groups were analyzed. We found that information such as age and sex was almost always reported. However, other important characteristics, such as race and ethnicity or socioeconomic background, were often missing or only described in limited detail. Very few studies analyzed whether device safety or effectiveness differed between groups. None of the trials formally compared their participant populations to the broader real-world populations affected by the condition being treated. These findings suggest that pivotal device trials may not consistently assess whether their results apply across diverse patient groups. Improving how equity-related information is reported and analyzed could help ensure that medical devices are evaluated in ways that better reflect the populations who use them.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Buzelli ML, Dawson S, Devane D, et al. Equity, diversity, and inclusion in pivotal medical device clinical investigations: a scoping review of studies published in the past 5 years. J Clin Epidemiol. 2026. PMID: 42285375. doi:10.1016/j.jclinepi.2026.112375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。